{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:01:16Z","timestamp":1790074876263,"version":"4.0.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>EuroQol Five-Dimension, 36-Item Short Form Health Survey, and Kidney Disease Quality of Life-36 were the most common instruments measuring health-related quality of life in trials of disease-modifying pharmacologic therapies in nondialysis CKD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Health-related quality-of-life effects were instrument and domain specific, seen more often in physical and kidney-specific domains of Kidney Disease Quality of Life-36.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Future CKD trials should use kidney-specific health-related quality-of-life measures, report all domains with multiple metrics, and discuss implications of design factors to aid interpretation.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several novel pharmacologic therapies for CKD have been shown to reduce risks of disease progression, cardiovascular events, and mortality. However, their effects on health-related quality of life (HRQoL) remain scattered across trials and are difficult to interpret, owing to variability in instruments used and other design-related factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed and Web of Science were searched for randomized clinical trials of pharmacologic interventions aimed at slowing CKD progression in adults with nondialysis CKD, published between January 2000 and January 2026. Two authors independently screened and extracted data. Data on study characteristics, HRQoL instruments used, and intervention effects were synthesized descriptively, and key methodological considerations were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 16,624 screened records, 13 trials collected HRQoL data. HRQoL was measured mainly using the EuroQol Five-Dimension questionnaire (EQ-5D) (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =8), 36-Item Short Form Health Survey (SF-36) (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =4), or Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =5). Nine trials reported the effects of interventions on HRQoL. Three demonstrated statistically significant effects in at least one HRQoL domain, all involving interventions that also slowed CKD progression. Effects were generally greater for physical than for mental health domains and were detected more frequently using the disease-specific KDQOL-36 questionnaire, particularly in the symptoms and effects domains, than using the generic EQ-5D instrument. Observed population average intervention effects were generally below conventional minimal clinically important difference thresholds at the population level, although individual-level benefits were evident.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The impact of disease-modifying therapies on HRQoL in nondialysis CKD was heterogeneous, instrument dependent, and domain specific.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.0000001210","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:01:34Z","timestamp":1785348094000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Health-Related Quality of Life in Clinical Trials of CKD Progression"],"prefix":"10.1681","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-9159","authenticated-orcid":false,"given":"Changyuan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Nephrology, Groningen Kolff Centre for Kidney Research, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"},{"name":"Department of Clinical Pharmacy and Pharmacology, Groningen Kolff Centre for Kidney Research, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7164-715X","authenticated-orcid":false,"given":"Devika","family":"Nair","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Geriatric Research Education and Clinical Center, Tennessee Valley Veterans Affairs Health System, Nashville, Tennessee"},{"name":"Veteran Wellbeing through Innovation Systems Science and Experience in Learning Health Systems (VETWISE-LHS) Center of Innovation, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Vart","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Groningen Kolff Centre for Kidney Research, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"},{"name":"Department of Clinical Pharmacy and Pharmacology, Groningen Kolff Centre for Kidney Research, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"24","key":"B1-20260922","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"23","key":"B2-20260922","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"2","key":"B3-20260922","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"6","key":"B4-20260922","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med."},{"issue":"7","key":"B5-20260922","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol."},{"issue":"8","key":"B6-20260922","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"B7-20260922","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2026.03.042","article-title":"Temporal trends in the complexity of nephrology inpatients: a population-based cohort study","volume":"88","author":"Ghimire","year":"2026","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B8-20260922","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.kint.2025.09.016","article-title":"Changing paradigms of studies in kidney diseases","volume":"108","author":"Levin","year":"2025","journal-title":"Kidney Int."},{"key":"B9-20260922","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7525-1-24","article-title":"A brief guide to the selection of quality of life instrument","volume":"1","author":"Hyland","year":"2003","journal-title":"Health Qual Life Outcomes."},{"key":"B10-20260922","doi-asserted-by":"crossref","first-page":"116720","DOI":"10.1016\/j.socscimed.2024.116720","article-title":"Exploring the measurement of health related quality of life and broader instruments: a dimensionality analysis","volume":"346","author":"Heijdra Suasnabar","year":"2024","journal-title":"Soc Sci Med."},{"issue":"1","key":"B11-20260922","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol."},{"issue":"7","key":"B12-20260922","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med."},{"issue":"6","key":"B13-20260922","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.ajkd.2006.02.175","article-title":"Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management","volume":"47","author":"Lash","year":"2006","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B15-20260922","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1681\/ASN.0000000776","article-title":"Effects of dapagliflozin on health-related quality of life in patients with CKD","volume":"37","author":"Bakker","year":"2026","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B16-20260922","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.ajkd.2009.05.011","article-title":"Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial","volume":"54","author":"Akizawa","year":"2009","journal-title":"Am J Kidney Dis."},{"issue":"7","key":"B17-20260922","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2014010042","article-title":"Randomized placebo-controlled EPPIC trials of AST-120 in CKD","volume":"26","author":"Schulman","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B18-20260922","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2215\/CJN.12011214","article-title":"A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction","volume":"11","author":"Cha","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10","key":"B19-20260922","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/ndt\/gfad037","article-title":"The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial","volume":"38","author":"Weir","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"15","key":"B20-20260922","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"2","key":"B21-20260922","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"key":"B22-20260922","doi-asserted-by":"crossref","first-page":"103338","DOI":"10.1016\/j.eclinm.2025.103338","article-title":"Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial","volume":"85","author":"Zhou","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"6","key":"B23-20260922","doi-asserted-by":"crossref","first-page":"100643","DOI":"10.1016\/j.xkme.2023.100643","article-title":"Lifestyle interventions, kidney disease progression, and quality of life: a systematic review and meta-analysis","volume":"5","author":"Neale","year":"2023","journal-title":"Kidney Med."},{"issue":"1","key":"B24-20260922","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ibd.20989","article-title":"Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany","volume":"16","author":"Stark","year":"2010","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"B25-20260922","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7326\/M22-2115","article-title":"Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease: a post hoc analysis of DAPA-CKD","volume":"176","author":"Schechter","year":"2023","journal-title":"Ann Intern Med."},{"issue":"6","key":"B26-20260922","doi-asserted-by":"crossref","first-page":"EVIDoa2300049","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evid."},{"issue":"11","key":"B27-20260922","doi-asserted-by":"crossref","first-page":"EVIDoa2500158","DOI":"10.1056\/EVIDoa2500158","article-title":"Cardiac effects of dapagliflozin in people with chronic kidney disease","volume":"4","author":"Bartholdy","year":"2025","journal-title":"NEJM Evid."},{"issue":"4","key":"B28-20260922","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2215\/CJN.06450710","article-title":"Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial","volume":"6","author":"Lewis","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B29-20260922","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ajh\/hpac124","article-title":"The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: a state-of-the-art review of the literature","volume":"36","author":"Georgianos","year":"2023","journal-title":"Am J Hypertens."},{"key":"B30-20260922","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"1","key":"B31-20260922","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2589-7500(23)00204-2","article-title":"Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (kidney BEAM): a multicentre, randomised controlled trial in the UK","volume":"6","author":"Greenwood","year":"2024","journal-title":"Lancet Digit Health."},{"issue":"10075","key":"B32-20260922","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet."},{"issue":"6","key":"B33-20260922","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","article-title":"Health-related quality of life and estimates of utility in chronic kidney disease","volume":"68","author":"Gorodetskaya","year":"2005","journal-title":"Kidney Int."},{"issue":"11","key":"B34-20260922","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/ndt\/gfab318","article-title":"The ASCEND-ND trial: study design and participant characteristics","volume":"37","author":"Perkovic","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B35-20260922","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.kint.2023.02.019","article-title":"The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease","volume":"103","author":"Johansen","year":"2023","journal-title":"Kidney Int."},{"issue":"10196","key":"B36-20260922","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(19)31388-1","article-title":"Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension","volume":"394","author":"Wesson","year":"2019","journal-title":"Lancet."},{"issue":"1","key":"B37-20260922","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ki.2008.414","article-title":"Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia","volume":"75","author":"Leaf","year":"2009","journal-title":"Kidney Int."},{"issue":"11","key":"B38-20260922","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1007\/s11136-016-1313-7","article-title":"Measuring health-related quality of life in patients with conservatively managed stage 5 chronic kidney disease: limitations of the medical outcomes study short form 36: SF-36","volume":"25","author":"Erez","year":"2016","journal-title":"Qual Life Res."},{"issue":"4","key":"B39-20260922","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials."},{"issue":"5","key":"B40-20260922","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care."},{"issue":"2","key":"B41-20260922","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"B53-20260922","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jval.2024.01.011","article-title":"Estimating a minimal important difference for the EQ-5D-5L utility index in dialysis patients","volume":"27","author":"Siriwardana","year":"2024","journal-title":"Value Health."},{"key":"B54-20260922","doi-asserted-by":"crossref","first-page":"111487","DOI":"10.1016\/j.jclinepi.2024.111487","article-title":"Systematic review reveals that EQ-5D minimally important differences vary with treatment type and may decrease with increasing baseline score","volume":"174","author":"Cheng","year":"2024","journal-title":"J Clin Epidemiol."},{"issue":"6","key":"B55-20260922","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1053\/j.ajkd.2019.08.026","article-title":"Perceived health and quality of life in patients with CKD, including those with kidney failure: findings from national surveys in France","volume":"75","author":"Legrand","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B42-20260922","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2369-13-19","article-title":"The association of moderate renal dysfunction with impaired preference-based health-related quality of life: third Korean national health and nutritional examination survey","volume":"13","author":"Lee","year":"2012","journal-title":"BMC Nephrol."},{"issue":"12","key":"B43-20260922","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.ekir.2020.09.028","article-title":"Health-related quality of life in people across the spectrum of CKD","volume":"5","author":"Krishnan","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B44-20260922","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12882-016-0312-9","article-title":"Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia","volume":"17","author":"Eriksson","year":"2016","journal-title":"BMC Nephrol."},{"issue":"9","key":"B46-20260922","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/ndt\/gfaa364","article-title":"Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort study","volume":"36","author":"Grams","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B47-20260922","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation."},{"issue":"5","key":"B48-20260922","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"B49-20260922","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ejhf.3263","article-title":"Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced\/preserved ejection fraction","volume":"26","author":"Yang","year":"2024","journal-title":"Eur J Heart Fail."},{"issue":"2","key":"B50-20260922","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00001648-199403000-00009","article-title":"The evolving concept of the healthy worker survivor effect","volume":"5","author":"Arrighi","year":"1994","journal-title":"Epidemiology."},{"key":"B51-20260922","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ymeth.2022.03.003","article-title":"Joint models for the longitudinal analysis of measurement scales in the presence of informative dropout","volume":"203","author":"Saulnier","year":"2022","journal-title":"Methods."},{"issue":"6","key":"B52-20260922","doi-asserted-by":"crossref","first-page":"e045105","DOI":"10.1136\/bmjopen-2020-045105","article-title":"SPIRIT-PRO extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials","volume":"11","author":"Calvert","year":"2021","journal-title":"BMJ Open."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:00:23Z","timestamp":1790071223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001210"}},"subtitle":["A Scoping Review"],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":53,"URL":"https:\/\/doi.org\/10.1681\/asn.0000001210","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"2026-04-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}